• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CYTH

    Cyclo Therapeutics Inc.

    Subscribe to $CYTH
    $CYTH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.

    IPO Year:

    Exchange: NASDAQ

    Website: cyclotherapeutics.com

    Recent Analyst Ratings for Cyclo Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Cyclo Therapeutics Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Cyclo Therapeutics Inc.

      15-12G - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      4/7/25 4:05:19 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/26/25 7:05:41 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/24/25 4:30:22 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      3/6/25 12:02:42 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      2/4/25 4:18:17 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      1/13/25 12:22:57 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      1/3/25 3:13:42 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      12/23/24 5:05:14 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 10-K/A filed by Cyclo Therapeutics Inc.

      10-K/A - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      12/18/24 4:04:07 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)

      12/5/24 4:34:50 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cyclo Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

      Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

      2/10/21 8:07:06 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cyclo Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Conkling William was granted 27,654 shares, increasing direct ownership by 55% to 77,884 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:25 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wong Vivien was granted 25,140 shares, increasing direct ownership by 63% to 64,853 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:45:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Cross Shawn was granted 28,597 shares, increasing direct ownership by 27% to 136,346 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:44:36 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Toig Randall M. was granted 33,311 shares, increasing direct ownership by 23% to 179,137 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:44:15 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Strattan Ce Rick was granted 30,169 shares, increasing direct ownership by 8% to 399,272 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:43:53 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Ostronic Francis Patrick was granted 70,329 shares, increasing direct ownership by 20% to 419,100 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:43:16 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sieger Markus was granted 58,138 shares, increasing direct ownership by 15% to 440,260 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      3/3/25 11:42:36 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Shanahan William S was granted 25,140 shares, increasing direct ownership by 17% to 173,966 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      2/28/25 8:07:31 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Conkling William was granted 16,660 shares, increasing direct ownership by 50% to 50,230 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      11/18/24 2:11:09 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Cross Shawn was granted 17,228 shares, increasing direct ownership by 19% to 107,749 units (SEC Form 4)

      4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)

      11/18/24 2:10:53 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cyclo Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Cyclo Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

      NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics' shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset

      3/26/25 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

      The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. "We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (NASDAQ:CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company's strategic focus will be on its lead clinical asset, T

      3/13/25 5:50:30 PM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

      First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and

      2/7/25 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

      Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in an oral presentation Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium™ being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral Presentation: Title: Trappsol® Cyclo™: Open Label Treatment in the Transp

      1/14/25 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

      NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. "We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the first calendar quarter of 2025 and closing promptly post shareholder approvals. Upon closing of the merger, the Company intends to focus its strategic efforts and resources on what will then be the Company's lead clinical program and core asset, Trappsol® Cyclo™. Accordingly, we are currently evaluating our other operating entities and portfolio of assets," said Bill Conkling, C

      12/11/24 7:00:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      Strategic merger with Rafael Holdings to combine two companies and advance Trappsol® Cyclo™ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to European Medicines Agency (EMA) targeted for H2 2025 Qualification for Priority Review Voucher expected upon NDA submission Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through sci

      11/14/24 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

      NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. "During fiscal 2024, we made significant progress on our strategy to advance our existing portfolio and to invest in, develop and commercialize clinical stage assets in areas of high unmet medical need. Specifically, we are extremely pleased to have entered into a merger agreement with Cyclo Therapeutics (NASDAQ:CYTH)," said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are encouraged that Cyclo Therapeutics has fully enrolled its pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the tre

      11/6/24 7:14:00 PM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

      TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company's financial operations. "We are delighted to welcome Shawn as our new Chief Financial Officer and look forward to his leadership and guidance as we invest in long-term growth and value creation while maintaining high standards in resource allocation and execution," said Frank D. Lee, chief executive officer of Pacira BioSciences. "Shawn brings a strong set of experienc

      10/21/24 8:00:00 AM ET
      $CYTH
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

      Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Trappsol® Cyclo™ demonstrated to be well tolerated in ongoing substudy with a safety profile consistent with that of completed phases Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines

      9/5/24 9:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/24 2:44:54 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/23 12:30:13 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cyclo Therapeutics Inc.

      SC 13G - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/10/23 4:28:56 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Cyclo Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

      – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha

      12/9/21 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

      Continued progress in lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter of 2021, and provided a business update. "We have executed on multiple fronts over the course of the third quarter. Our pivotal Phase 3 study evaluating Trappsol® Cyclo™ as a potential treatment for Niemann-Pick Disease, TransportNPC™,

      11/15/21 4:20:00 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer's Disease Asset

      – Dr. Lemere is a renowned translational researcher focused on understanding, preventing, and treating Alzheimer's disease – Company continues to advance evaluation of Trappsol® Cyclo™ toward Phase 2 study in Alzheimer's disease with investigational new drug application (IND) filing on track before year end Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Cynthia A. Lemere, PhD as Senior Advisor for its Alzheimer's disease program. Dr. Lemere is a distinguishe

      11/2/21 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

      - Dr. Kjems is a leading global physician scientist with a proven pharma track record of drug development across multiple therapeutic areas, including chronic indications, oncology and rare diseases - - Gerald F. Cox, MD, PhD will continue offering clinical development leadership, worldwide regulatory expertise and access to expansive network as a member of the Company's Scientific Advisory Board - Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjem

      9/27/21 8:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy

      Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communities Formerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, announced today it has appointed Lori McKenna Gorski as Global Head of Patient Advocacy. "The unmet needs of patients and their families remain at the forefront for Cyclo Therapeutics as we drive the develo

      5/11/21 9:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

      GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced the appointment of Russ Belden as Acting Chief Commercial Officer. Mr. Belden is a commercialization leader with over 33 years of senior leadership experience in the biotechnology industry, specializing in strategic marketing, sales management, sales training, and product development. Through his firm, Mr. Belden has worked with over 60 pre-clinical, early-launch phase therapeutics and

      3/10/21 8:35:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer

      GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced the appointment of Gerald F. Cox, MD, PhD as Acting Chief Medical Officer. Dr. Cox is an internationally renowned biotechnology executive with over 20 years of experience in drug development for rare diseases. Over the course of his career, he has made major contributions to more than 15 Investigational New Drug applications (INDs) and 6 orphan drug marketing authorizations for serious and life-threate

      3/1/21 9:05:00 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care